List of Excipients in Branded Drug SINUVA

« Back to Dashboard

SINUVA Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

SINUVA is a locally delivered, bioabsorbable mometasone furoate sinus implant for adults with chronic rhinosinusitis with nasal polyps who previously underwent ethmoid sinus surgery. Its commercial differentiation comes from the combination of a corticosteroid, a resorbable polymer matrix, and a self-expanding implant geometry that delivers drug directly to the sinus cavity for an extended period. The strongest excipient opportunities are in polymer composition, degradation control, drug loading, implant mechanics, and manufacturing protection rather than in conventional oral dosage-form excipients.

What is SINUVA and how does its delivery system work?

SINUVA contains 1,350 micrograms of mometasone furoate in a bioabsorbable sinus implant. The product is inserted through the nasal passage and expands within the ethmoid sinus cavity. It is intended to maintain local contact while releasing mometasone and gradually resorbing over approximately 90 days, according to FDA product information.[1]

Attribute	SINUVA
Active ingredient	Mometasone furoate
Dose per implant	1,350 mcg
Dosage form	Bioabsorbable sinus implant
Administration	Intranasal placement into the ethmoid sinus
Target population	Adults with chronic rhinosinusitis with nasal polyps and prior ethmoid sinus surgery
FDA application	NDA 209310
Regulatory pathway	New drug application for a drug-device combination
Release objective	Local corticosteroid delivery over an extended period
Commercial owner	Medtronic, following its acquisition of Intersect ENT
Initial FDA approval	December 2017

The product is not a conventional nasal spray. Its value depends on local residence time, physical expansion, controlled drug elution, tolerability, and placement accuracy.

What excipients are used in SINUVA?

The FDA prescribing information identifies a bioabsorbable polymer as the principal inactive structural material but does not provide a complete qualitative and quantitative excipient composition in the public label.[1] The commercial formulation is therefore best analyzed as a polymer-based drug-device system rather than as a conventional excipient blend.

Functional excipient categories

The SINUVA excipient platform performs several functions simultaneously:

1. It holds and distributes mometasone furoate.
2. It controls drug release.
3. It provides mechanical expansion after placement.
4. It maintains local contact with the sinus cavity.
5. It gradually loses mass through biodegradation.
6. It limits the need for surgical removal.

The polymer is therefore part of the product’s critical quality attributes. Changes in polymer molecular weight, monomer ratio, crystallinity, porosity, residual solvent, or processing temperature could affect both product performance and clinical exposure.

Why mometasone furoate is suitable for a polymer implant

Mometasone furoate is a potent glucocorticoid with low systemic bioavailability when administered intranasally. Its potency allows a relatively small drug load to produce a local anti-inflammatory effect. The molecule’s lipophilicity and low aqueous solubility also support controlled-release formulation strategies, although they create challenges for content uniformity and release testing.

The formulation objective is not maximum dissolution. It is controlled local delivery without an early burst that could increase systemic exposure or produce excessive local concentrations.

What excipient strategy does SINUVA use?

SINUVA’s excipient strategy is based on controlled biodegradation and mechanical residence rather than chemical enhancement of absorption.

Polymer selection

The polymer must balance four competing requirements:

Requirement	Commercial relevance
Sufficient mechanical strength	Allows delivery and deployment in the sinus
Controlled water uptake	Influences drug diffusion and polymer degradation
Predictable resorption	Reduces the need for retrieval
Low local inflammatory response	Supports tolerability and repeat-use potential

A faster-degrading polymer could produce a higher early release rate and shorter residence time. A slower-degrading polymer could extend exposure but create a longer-lived foreign-body burden. The optimal profile depends on sinus anatomy, mucus clearance, postoperative inflammation, and the intended treatment interval.

Public FDA labeling does not disclose a full polymer specification. That lack of disclosure creates an opportunity for suppliers with proprietary resorbable polymers, but it also limits the ability of competitors to reproduce the product through label review alone.

Drug loading and distribution

Mometasone furoate must be distributed consistently throughout the implant. Uneven loading can produce variable release, potency differences between implant segments, and a nonuniform exposure profile.

Relevant formulation controls include:

• Particle size and morphology of mometasone furoate
• Drug-polymer compatibility
• Mixing homogeneity
• Thermal exposure during processing
• Residual solvent levels
• Implant mass and dimensions
• Content uniformity
• In vitro release profile

Because the drug load is only 1,350 micrograms, small absolute manufacturing deviations can have a material effect on dose uniformity.

Implant geometry as a formulation variable

The excipient system cannot be separated from the implant design. SINUVA uses a self-expanding structure that is intended to remain in the ethmoid sinus after delivery. The geometry controls tissue contact, fluid access, and the surface area available for drug release.

This creates potential protection around:

• Petal configuration
• Expansion force
• Implant diameter
• Delivery catheter compatibility
• Polymer thickness
• Drug-loaded versus drug-free structural regions
• Deployment and retrieval characteristics

For competitors, reproducing the drug composition may be easier than reproducing the combination of expansion behavior, placement reliability, and release performance.

What formulation patents could protect SINUVA?

SINUVA’s commercially relevant intellectual property is likely to extend beyond the active ingredient. The most valuable claim categories are formulation and drug-device claims that connect the polymer, mometasone, implant structure, and treatment method.

Likely formulation claim categories

Potentially relevant claims include:

• A bioabsorbable implant containing mometasone furoate
• Defined drug-to-polymer ratios
• Controlled release over a specified period
• Implant structures that expand within the sinus
• Drug elution from a resorbable polymer matrix
• Use after ethmoid sinus surgery
• Treatment of nasal polyps or chronic rhinosinusitis
• Deployment through a delivery system
• Polymer compositions with defined degradation characteristics

These claim types can create multiple barriers even when the active pharmaceutical ingredient is old and widely available.

Why composition-of-matter protection is limited

Mometasone furoate is an established corticosteroid. A new entrant is unlikely to obtain broad composition-of-matter protection covering the molecule itself. Commercial protection instead depends on:

• Formulation patents
• Device patents
• Drug-device combination claims
• Method-of-use claims
• Manufacturing-process patents
• Trade secrets covering polymer processing and release control

A competitor may avoid one patent family by changing the polymer or implant geometry. That approach can still trigger infringement risk under other formulation or use claims.

What is the FDA regulatory status of SINUVA?

SINUVA was approved by the FDA in December 2017 under NDA 209310 for adults with chronic rhinosinusitis with nasal polyps who had undergone ethmoid sinus surgery.[1] The product is regulated as a drug-device combination, with drug quality, device performance, sterility, biocompatibility, and delivery requirements considered together.

The regulatory burden for a follow-on product is higher than for a conventional mometasone nasal spray. A sponsor would need to address:

• Drug identity, strength, purity, and potency
• Polymer characterization
• Implant dimensions and mechanical performance
• Sterility assurance
• Biocompatibility
• Degradation products
• Local tissue exposure
• Systemic corticosteroid exposure
• Delivery-system performance
• In vitro and clinical release comparability

A follow-on sponsor would also need to establish that the implant can be placed reliably in the relevant sinus anatomy and that its release profile supports the proposed clinical use.

When does SINUVA lose regulatory exclusivity?

SINUVA received the standard three-year exclusivity associated with approval based on new clinical investigations, subject to FDA’s statutory exclusivity determination.[2] That exclusivity does not prevent all forms of competition, but it can delay certain abbreviated applications that rely on the approved clinical data.

SINUVA does not have biologic exclusivity because mometasone furoate is a small molecule. Biosimilar competition is therefore not the relevant pathway. The principal risks are generic or follow-on drug-device products submitted through an abbreviated application or a 505(b)(2) application.

Protection category	Relevance to SINUVA
New chemical entity exclusivity	Not the primary basis because mometasone furoate was previously known
Three-year clinical-investigation exclusivity	Relevant to the 2017 approval
Orphan-drug exclusivity	Not identified as the basis for approval
Biologic exclusivity	Not applicable
Patent exclusivity	Depends on issued and listed claims
Device protection	May cover implant geometry, delivery, and deployment
Trade-secret protection	May cover polymer processing and release testing

What is the Orange Book status of SINUVA?

SINUVA is associated with NDA 209310. The FDA Orange Book is the controlling source for currently listed patents and pediatric exclusivity associated with the NDA.[3] Public product labeling identifies the application and approved use but does not itself provide a complete patent schedule.

The commercially relevant Orange Book questions are:

1. Whether any drug patents are listed against NDA 209310.
2. Whether listed patents cover the drug, the implant, or the method of use.
3. Whether the claims are eligible for listing under FDA rules.
4. Whether a generic applicant would need to submit a Paragraph IV certification.
5. Whether the patent owner has filed timely litigation after receiving a Paragraph IV notice.

For SINUVA, device and formulation claims may have greater practical importance than traditional active-ingredient patents. A patent not listed in the Orange Book can still create litigation exposure, but it may not generate the same automatic stay consequences associated with a timely Paragraph IV action.

Which companies are challenging SINUVA?

No widely reported Paragraph IV challenge or major patent litigation campaign against SINUVA is identified in the FDA approval materials and publicly documented company disclosures cited here. The absence of a public challenge does not eliminate future competition risk.

Potential entrants include:

• Generic drug manufacturers with experience in 505(b)(2) products
• Nasal drug-delivery companies
• ENT device manufacturers
• Specialty pharmaceutical companies
• Contract manufacturers with biodegradable implant capabilities

The most credible challengers are likely to pursue a modified implant rather than a direct copy. A differentiated polymer, alternative steroid loading, different residence time, or redesigned delivery catheter could reduce reliance on the reference product’s technical design.

What generic entry risks exist for SINUVA?

The likely entry path is more complex than an ANDA for a simple nasal spray. A follow-on sponsor could pursue an ANDA if FDA determines that the product can meet the applicable requirements for sameness and therapeutic equivalence. A 505(b)(2) application may be more practical if the sponsor relies on the SINUVA clinical record while introducing differences in formulation, device design, release profile, or manufacturing.

Generic launch scenarios

Scenario	Probability driver	Commercial effect
Direct abbreviated product	Requires close formulation and device similarity	Earlier price competition but higher patent and equivalence risk
505(b)(2) modified implant	Allows differences supported by new data	Longer development timeline and potentially differentiated pricing
Alternative steroid implant	Avoids direct mometasone replication	Creates a new clinical and regulatory evidence burden
Lower-cost procedure-linked product	Focuses on outpatient ENT economics	Could pressure physician adoption and reimbursement
Combination device with revised deployment system	Differentiates placement and usability	May compete on procedural efficiency rather than price

A follow-on product must demonstrate more than mometasone equivalence. It must address the product’s local performance, resorption, implantation, and release characteristics.

What patent and manufacturing barriers protect SINUVA?

The strongest barriers are likely to be manufacturing and product-performance barriers.

Manufacturing controls

Commercial-scale production may require tight control over:

• Polymer drying and moisture content
• Drug dispersion
• Extrusion or molding conditions
• Implant dimensions
• Mechanical expansion force
• Sterilization exposure
• Residual monomers and solvents
• Package integrity
• In vitro release testing

Small changes in moisture or thermal history can alter polymer degradation and release kinetics. These parameters may be difficult to reverse-engineer from the marketed implant.

Trade-secret value

Trade secrets may cover:

• Polymer grade selection
• Mixing sequence
• Processing temperature
• Drug particle preparation
• Conditioning time
• Sterilization cycle
• Release-test methods
• Acceptance criteria
• Device deployment settings

Trade-secret protection does not block independent development, but it can increase development cost and delay competitive entry.

How strong is the SINUVA patent estate?

SINUVA’s patent strength should be assessed as a layered product estate rather than through a single active-ingredient patent.

Estate layer	Relative strategic value
Mometasone composition patents	Low for new exclusivity because the molecule is established
Polymer-drug formulation patents	High if claims cover release and composition ranges
Implant geometry patents	High if the geometry is required for sinus placement
Delivery-system patents	Moderate to high depending on design-around options
Method-of-use patents	Moderate, with value tied to approved indications and claim scope
Manufacturing patents	Moderate, especially where process parameters affect product quality
Trade secrets	High operational value but difficult to enforce against independent development

A strong estate would combine formulation claims with implant and method-of-use claims. A narrow estate limited to one polymer composition would be more vulnerable to a redesigned product.

What commercial opportunities exist in SINUVA excipients?

The commercial opportunity is broader than supplying an inactive ingredient. Suppliers can participate in the product platform through materials, processing, testing, and lifecycle management.

High-value excipient opportunities

1. Resorbable polymer platforms

A supplier could develop polymers with tunable degradation windows, lower residual monomer levels, improved drug dispersion, or more predictable mechanical behavior.

2. Controlled-release steroid implants

Mometasone is one opportunity, but similar platforms could deliver other locally acting corticosteroids or anti-inflammatory agents for ENT applications.

3. Polymer-processing services

Specialized contract manufacturers could offer implant molding, extrusion, drug dispersion, sterilization validation, and release testing.

4. Next-generation sinus implants

Commercial differentiation could focus on:

• Longer residence
• Shorter residence
• Lower total steroid load
• Improved deployment
• Smaller delivery profile
• Reduced retrieval procedures
• Better placement in difficult anatomy

5. Analytical and quality-control platforms

Testing services for degradation products, drug release, polymer molecular weight, extractables, leachables, and implant mechanics have recurring commercial value.

How does SINUVA compare with conventional mometasone nasal sprays?

SINUVA and mometasone nasal sprays use the same active ingredient but address different delivery problems.

Factor	SINUVA	Mometasone nasal spray
Delivery site	Sinus cavity after placement	Nasal mucosa
Dosing behavior	Single implanted dose with extended release	Repeated patient-administered doses
Adherence burden	Lower after implantation	Ongoing daily administration
Device complexity	High	Low to moderate
Manufacturing complexity	High	Moderate
Follow-on pathway	Drug-device and local delivery issues	More conventional generic pathway
Excipient value	Polymer and implant architecture	Suspension, preservative, surfactant, and spray-performance controls
Commercial differentiation	Residence, release, and procedure integration	Price, spray device, tolerability, and convenience

The implant can command a premium when physicians and payers value sustained local treatment and reduced daily dosing. Its adoption remains sensitive to procedure logistics, reimbursement, training, and the need for prior sinus surgery.

What revenue exposure does SINUVA create for Medtronic?

Medtronic acquired Intersect ENT in 2022 in a transaction valued at approximately $1.1 billion, expanding its ear, nose, and throat portfolio.[4] SINUVA is commercially relevant within a broader ENT franchise that includes sinus implants, surgical navigation, and related procedural technologies.

Public company reporting does not consistently disclose SINUVA revenue as a separate line item. Revenue exposure is therefore best assessed through:

• Procedure volumes
• ENT physician adoption
• Reimbursement for sinus implants
• Repeat implantation rates
• Hospital and ambulatory surgery center purchasing
• Competitive products
• Generic or 505(b)(2) entry
• Expansion into adjacent chronic rhinosinusitis populations

The main commercial risk is not only price erosion. A competing implant could affect procedure preference, physician training, and platform-level purchasing decisions.

Key Takeaways

• SINUVA is a 1,350-microgram mometasone furoate bioabsorbable sinus implant approved under NDA 209310.
• Its excipient strategy centers on a resorbable polymer matrix that controls drug release and supports implant residence.
• The highest-value intellectual property is likely to involve polymer composition, release kinetics, implant geometry, delivery systems, and manufacturing processes.
• Biosimilar competition is not applicable. Generic and 505(b)(2) drug-device products are the relevant follow-on risks.
• A direct copy may face formulation, device, patent, and equivalence barriers. A modified implant could provide a more realistic competitive route.
• Excipient suppliers can pursue opportunities in biodegradable polymers, implant processing, release testing, and next-generation local steroid delivery.
• SINUVA’s commercial performance is linked to ENT procedure economics, reimbursement, physician adoption, and the wider Medtronic ENT platform.

FAQs

Is SINUVA an implant or a nasal spray?

SINUVA is a bioabsorbable sinus implant. It is placed in the ethmoid sinus and is not administered as a conventional nasal spray.

What polymer is in the SINUVA implant?

FDA labeling identifies a bioabsorbable polymer but does not provide a full public qualitative and quantitative formulation disclosure. The polymer’s grade, processing conditions, and degradation profile are commercially important formulation variables.

Can a generic company copy SINUVA using mometasone furoate?

A company may pursue a follow-on product, but it would need to address the implant, delivery system, polymer matrix, local release, sterility, and clinical or equivalence requirements. A modified 505(b)(2) product may be more feasible than an exact copy.

Does SINUVA have biosimilar risk?

No. Mometasone furoate is a small molecule, so the relevant competition is generic or follow-on drug-device competition rather than biosimilar substitution.

What is the main commercial opportunity in SINUVA excipients?

The main opportunity is a tunable bioabsorbable polymer platform that provides predictable drug release, adequate deployment strength, low local irritation, and scalable manufacturing for sinus implants.

References

1. U.S. Food and Drug Administration. (2017). SINUVA mometasone furoate sinus implant: Prescribing information.
2. U.S. Food and Drug Administration. (2017). SINUVA approval letter, NDA 209310.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Medtronic plc. (2022). Medtronic completes acquisition of Intersect ENT.